Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (201-210 of 443) with videos related to

Pageof 45
Sort By:
Bone Marrow Transplantation|October 12, 2022
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantationAnne Banet, Ali Bazarbachi, Myriam Labopin, et al.
Haematologica|October 7, 2008
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcomePaola Ballerini, Judith Landman-Parker, Jean Michel Cayuela, et al.
Oncotarget|April 2, 2016
High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationTomasz Czerw, Myriam Labopin, Christoph Schmid, et al.
Blood Cancer Journal|March 5, 2020
Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemiaAnn-Kristin Schmaelter, Myriam Labopin, Gerard Socié, et al.
Frontiers in Immunology|April 17, 2020
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)Robert David Sandler, Rachel Scarlett Tattersall, Helene Schoemans, et al.
Haematologica|May 12, 2018
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationDalila Salvatore, Myriam Labopin, Annalisa Ruggeri, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Michael Potter, et al.
American Journal of Hematology|March 15, 2018
Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) studyZhuoyan Li, Myriam Labopin, Fabio Ciceri, et al.
Hemasphere|October 19, 2022
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
Bone Marrow Transplantation|December 9, 2020
Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working PartyKlaus Hirschbühl, Myriam Labopin, Mohamed Houhou, et al.
Pageof 45

Showing results (201-210 of 443) with videos related to

Sort By:
Pageof 45
Bone Marrow Transplantation|October 12, 2022
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantationAnne Banet, Ali Bazarbachi, Myriam Labopin, et al.
Haematologica|October 7, 2008
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcomePaola Ballerini, Judith Landman-Parker, Jean Michel Cayuela, et al.
Oncotarget|April 2, 2016
High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationTomasz Czerw, Myriam Labopin, Christoph Schmid, et al.
Blood Cancer Journal|March 5, 2020
Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemiaAnn-Kristin Schmaelter, Myriam Labopin, Gerard Socié, et al.
Frontiers in Immunology|April 17, 2020
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)Robert David Sandler, Rachel Scarlett Tattersall, Helene Schoemans, et al.
Haematologica|May 12, 2018
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationDalila Salvatore, Myriam Labopin, Annalisa Ruggeri, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Michael Potter, et al.
American Journal of Hematology|March 15, 2018
Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) studyZhuoyan Li, Myriam Labopin, Fabio Ciceri, et al.
Hemasphere|October 19, 2022
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
Bone Marrow Transplantation|December 9, 2020
Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working PartyKlaus Hirschbühl, Myriam Labopin, Mohamed Houhou, et al.
Pageof 45